SCHEMBL16640318

SCHEMBL16640318

CC(C)c1ccc(-n2c3ccccc3c3cccnc32)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 5/20 0.41
PDE4B Q07343 5/20 0.41
PDE4C Q08493 5/20 0.41
PDE4D Q08499 5/20 0.41
KDM4E B2RXH2 2/20 0.41
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPT P10636 2/20 0.40
FEN1 P39748 1/20 0.40
ALDH1A1 P00352 3/20 0.39
TSHR P16473 2/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 2/20 0.37
NOTUM Q6P988 1/20 0.36
LMNA P02545 2/20 0.36
MEN1 O00255 1/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13236508 0.86 RXFP1 (0.47) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL23490972 0.85 PPARG (0.43) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL11978691 0.83 CYP2C19 (0.49) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL5021418 0.83 AKT1 (0.46) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL261813 0.83 KDM4E (0.47) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL5021401 0.82 KDM4E (0.61) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL16640348 0.82 L3MBTL1 (0.41) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL1102414 0.82 KDM4E (0.59) KDM4EATML3MBTL1MAPTALDH1A1
SCHEMBL16640316 0.82 GRM4 (0.35) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL16640330 0.82 PDE4A (0.37) PDE4APDE4BPDE4CPDE4DKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11189808-B2 Platinum complexes and devices ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2021-11-30 US disclosed
US-20200152891-A1 PLATINUM COMPLEXES AND DEVICES UNIV ARIZONA STATE (US) 2020-05-14 US disclosed
US-10566553-B2 Platinum complexes and devices ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2020-02-18 US disclosed
US-9947881-B2 Platinum complexes and devices ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-04-17 US disclosed
US-9947881-B2 Platinum complexes and devices ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-04-17 US disclosed
US-20170012224-A1 PLATINUM COMPLEXES AND DEVICES ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2017-01-12 US disclosed
US-9385329-B2 Platinum complexes and devices Arizona Board of Regents on behalf of Arizona State University and Universal Display Corporation (US) 2016-07-05 US disclosed
US-20150105556-A1 PLATINUM COMPLEXES AND DEVICES ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11189808-B2 Platinum complexes and devices OXA1L, OCIAD1, OCIAD2 PDE4A 4870/4885PDE4B 4878/4885PDE4C 4843/4885
US-10566553-B2 Platinum complexes and devices OXA1L, OCIAD1, OCIAD2 PDE4A 4870/4885PDE4B 4878/4885PDE4C 4843/4885
US-20200152891-A1 PLATINUM COMPLEXES AND DEVICES OXA1L, OCIAD1, OCIAD2 PDE4A 4870/4885PDE4B 4878/4885PDE4C 4843/4885
US-20170012224-A1 PLATINUM COMPLEXES AND DEVICES OXA1L, OCIAD1, OCIAD2 PDE4A 4870/4885PDE4B 4878/4885PDE4C 4843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.